## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($314.09)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Up 37% Since August, Is It Safe to Buy UnitedHealth Group Stock Again?**
- Source: Finviz | 20251204T071046 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) has seen its stock rally 37% since August, despite facing challenges such as rising costs and a DOJ investigation. This rebound was significantly influenced by Berkshire Hathaway's investment, highlighting the stock's perceived value. While UnitedHealth is actively trying to improve its financials and has raised its guidance, it still faces an uncertain path, making patience crucial for investors.

**2. UnitedHealth Group Stock (UNH) Rallies on Analyst Upgrades, Latin America Exit and New ETF: December 3, 2025 Outlook**
- Source: ts2.tech | 20251203T183741 | Bullish | Relevance: 100%
- UnitedHealth Group (UNH) stock rallied on December 3, 2025, driven by analyst upgrades, the company's strategic exit from Latin America, and the launch of a new single-stock ETF. Despite a turbulent year marked by a cyberattack and fraud probe, the stock saw a significant bounce due to a $1.6 billion investment from Warren Buffett and renewed bullish sentiment from Wall Street. The article deep dives into the catalysts, Q3 2025 earnings, strategic recalibrations for Medicare Advantage, and ongoing legal and regulatory challenges facing UNH.

**3. Why UnitedHealth (UNH) Stock Is Up Today**
- Source: Finviz | 20251203T152500 | Bullish | Relevance: 100%
- UnitedHealth (UNH) shares rose 4.5% due to positive analyst actions and strategic company updates, including lifted price targets by Wolfe Research, Bernstein, and RBC Capital. The optimism stems from the belief that UnitedHealth can improve profit margins in its insurance division. This move follows a previous gain tied to hopes for an interest rate cut, though the stock is still significantly down year-to-date.

**4. Wells Fargo Analyst has a Positive Outlook on UnitedHealth Group (UNH)**
- Source: Finviz | 20251202T010200 | Somewhat-Bullish | Relevance: 100%
- Wells Fargo analyst Stephen Baxter assigned a Buy rating to UnitedHealth Group (UNH) with a price target of $400. This comes amidst ongoing discussions between UnitedHealthcare and TriHealth regarding compensation, which could lead to TriHealth providers leaving UNH's network and affecting up to 80,000 patients. UnitedHealth Group is noted as a strong dividend stock, providing health benefit plans and services.

**5. A year after the killing of UnitedHealthcareâ€™s CEO, Luigi Mangione fights to suppress key evidence**
- Source: Fortune | 20251204T160933 | Somewhat-Bearish | Relevance: 100%
- Luigi Mangione is fighting to suppress key evidence in the murder case of UnitedHealthcare CEO Brian Thompson, including his statements to law enforcement and items seized from his backpack. The defense argues that Mangione's statements were taken before he was read his rights and that the search of his backpack was conducted without a warrant. This high-stakes hearing provides a preview of the evidence relevant to both state and federal charges against Mangione.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 8.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 18.8x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $300.6B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 18.8 |
| Current P/E | 20.4 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 3.3pp (needs >4.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (2.52), confirming momentum. RSI neutral at 52. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.67% (CS: 59) | Neutral |
| RSI_14 | 52.0 | Neutral |
| MACD Histogram | 2.52 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 0.919x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $333.49
- **Stop Loss:** $314.09 (5.8% risk)
- **Target:** $372.29 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $8,337.25
- **Portfolio %:** 8.34%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*